ALK and anaplastic large cell lymphoma: The Children’s Oncology Group designed a randomized phase II clinical trial (NCT01979536) to determine the tolerability, EFS, and OS of adding either brentuximab vedotin or crizotinib to ALCL99 chemotherapy in children and adolescents with systemic ALK+/CD30+ ALCL (40, 52).